Molecular Partners saw the highest growth of 0.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Molecular Partners’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Molecular Partners has been focused on protecting inventions in United States(US) with six publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 86% of filings. The United States(US), and Australia(AU) patent Office are among the top ten patent offices where Molecular Partners is filings its patents..
Immatics and Roche could be the strongest competitors for Molecular Partners
Leukemia related patents lead Molecular Partners portfolio followed by solid tumor
Molecular Partners has highest number of patents in leukemia followed by solid tumor.
For comprehensive analysis of Molecular Partners's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
